NCT06308406 2024-04-11
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
Clinical Trials
24 trialsNCT04780217 2024-03-04
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
ImmVira Pharma Co. Ltd
Phase 1/2 Unknown
NCT04938583 2023-10-17
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
CanariaBio Inc.
Phase 1/2 Unknown
NCT03382340 2023-09-28
IMX-110 in Patients With Advanced Solid Tumors
Immix Biopharma, Inc.
Phase 1/2 Unknown
NCT05965141 2023-07-28
Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2 Unknown
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT03362606 2019-09-19
Engineered Immune Effectors Against Ovarian Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT03916679 2019-04-16
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Unknown
NCT03634501 2019-01-11
Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells
Xuanwu Hospital, Beijing
Phase 1/2 Unknown
NCT01650376 2018-03-23
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Swedish Medical Center
Phase 1/2 Unknown
NCT02684318 2017-06-22
Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
Poveda, Andrés, M.D.
Phase 1/2 Unknown
NCT01600573 2016-10-11
Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
Charite University, Berlin, Germany
Phase 1/2 Unknown
NCT02244502 2016-09-21
Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)
NovoCure Ltd.
Phase 1/2 Unknown
NCT00660101 2015-12-03
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
AVAX Technologies
Phase 1/2 Unknown
NCT02052128 2015-06-24
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Arno Therapeutics
Phase 1/2 Unknown
NCT00553683 2014-01-14
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Unknown
NCT00003064 2014-01-06
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00886717 2013-08-02
Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00551122 2013-01-23
GemTIP
University of Southampton
Phase 1/2 Unknown
NCT01724944 2012-11-12
LYANA
Catholic University of the Sacred Heart
Phase 1/2 Unknown
NCT01584115 2012-04-25
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
Instituto de Investigação em Imunologia
Phase 1/2 Unknown
NCT00075543 2008-07-24
Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00057395 2005-06-24
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
Aronex Pharmaceuticals
Phase 1/2 Unknown